Literature DB >> 29805812

Erector Spinae Plane Block for Elective Laparoscopic Cholecystectomy in the Ambulatory Surgical Setting.

Kjartan Eskjaer Hannig1, Christian Jessen1, Uday Kant Soni1, Jens Børglum2, Thomas Fichtner Bendtsen3.   

Abstract

Postoperative pain after laparoscopic cholecystectomy can be severe. Despite multimodal analgesia regimes, administration of high doses of opioids is often necessary. This can further lead to several adverse effects such as drowsiness and respiratory impairment as well as postoperative nausea and vomiting. This will hinder early mobilization and discharge of the patient from the day surgery setting and is suboptimal in an Early Recovery after Surgery setting. The ultrasound-guided Erector Spinae Plane (ESP) block is a novel truncal interfascial block technique providing analgesia of the thoracic or abdominal segmental innervation depending on the level of administration. Local anesthetic penetrates anteriorly presumably through the costotransverse foramina to the paravertebral space. We demonstrate the analgesic efficacy of the ESP block in a case series of three patients scheduled for ambulatory laparoscopic cholecystectomy.

Entities:  

Year:  2018        PMID: 29805812      PMCID: PMC5899876          DOI: 10.1155/2018/5492527

Source DB:  PubMed          Journal:  Case Rep Anesthesiol        ISSN: 2090-6390


1. Introduction

Laparoscopic cholecystectomy is associated with moderate to severe pain despite all currently available multimodal analgesic regimes [Anesthesia & Analgesia. 1993 ">1-3]. The ultrasound-guided Erector Spinae Plane (ESP) block is a novel truncal interfascial regional technique [4]. Two variations of the ESP block for thoracic and abdominal procedures have recently been described in literature. The injection site is either at the level of T5 transverse process, resulting in spread between the C7 and T8 segmental levels [4-6], or at the levels of the T7-T9 transverse processes, resulting in spread between the T6 and T12 segmental levels [7-9]. Local anesthetic penetrates anteriorly presumably through the costotransverse foramina to the paravertebral space and it can thus be described as an indirect paravertebral block [8]. Several approaches targeting the same interfascial plane have been described in the current literature with variable injection sites [10, 11]. However, the ESP block is presumably the most promising due to its anatomically close proximity to the costotransverse foramina.

2. Case Presentation

Written informed consent for publication was obtained from all three patients. There was no need for approval by the Central Denmark Region Committees on Biomedical Research Ethics.

2.1. Patient 1

A 42-year-old man with a body mass index (BMI) of 35.8 kg/m2 presented for elective ambulatory laparoscopic cholecystectomy. He was diagnosed with obstructive sleep apnea treated with nightly continuous positive airway pressure (CPAP) therapy. He was otherwise healthy and did not take any medication. A bilateral ESP block was performed just prior to surgery. The patient was sitting up and the level of the T7 transverse process was located just 3 cm laterally from the midline using a 15–6 MHz linear ultrasound probe (SonoSite, X-Porte, Bothell, Washington) oriented sagittally (Figure 1). The cross-sectional view of the transverse process was centered on the ultrasound screen and the overlying trapezius, and erector spinae muscles were identified. Under aseptic conditions, a 22-gauge 80 mm block needle (Pajunk, Geisingen, Germany) was inserted in-plane at a shallow angle of approximately 30–40° in a cranial-to-caudal direction aiming at the needle tip at the posterior aspect of the transverse process. Bony contact was established, and hydrodissection with 2 mL of isotone saline confirmed correct needle tip position on the transverse process and deep to the epimysium of the erector spinae muscle. The needle tip was then redirected and advanced slightly caudad to the transverse process. After hydrodissection with yet another 2 mL of isotonic saline, injection of 20 mL ropivacaine 0.5% was performed ensuring both cranial and caudal spread of local anesthetic in the fascial plane deep to the erector spinae muscle, lifting the muscle off the transverse processes. The procedure was repeated in a similar fashion on the contralateral side. Preoperative multimodal analgesia was achieved with paracetamol 1 g and ibuprofen 400 mg orally. General anesthesia was induced with propofol 180 mg and remifentanil 350 μg and maintained with propofol 65 μg/kg/min and remifentanil 0.33 μg/kg/min. Intubation was uneventful. The patient received intraoperative dexamethasone 8 mg IV, droperidol 0.625 mg IV, and ondansetron 4 mg IV. Fentanyl 50 μg IV was also administered intraoperatively 30 min prior to emergence from anesthesia. Pneumoperitoneum was achieved with insufflation of carbon dioxide (CO2) with a pressure of 12 mmHg. At the end of the uncomplicated surgical procedure the laparoscopic port sites were infiltrated with 20 mL of ropivacaine 0.2%, and CO2 was evacuated. Extubation was uneventful but in the postanesthesia care unit (PACU), the patient was drowsy and complained about dyspnea, which was suspected to be caused by a combination of mild intermittent airway obstruction, anxiety, and pain. It was thus treated with a nasal airway, fentanyl 50 μg IV, and morphine 10 mg orally. Once fully awake, the patient denied that the incident was due to pain but reported that he had been anxious because of dyspnea. Numerical rating scale (NRS) was 2/10 and remained below 3/10 for the rest of his stay in the PACU and he did not receive any further medication. He was discharged to home 2 hours and 56 min after arriving in the PACU.
Figure 1

Ultrasound image showing subcutis, trapezius muscle, erector spinae muscle, transverse process of T7 (TP), needle path (in red), and spread of local anesthetic (LA).

2.2. Patient 2

A 49-year-old woman (BMI 28.4 kg/m2) was scheduled for ambulatory laparoscopic cholecystectomy. She did not present any comorbidities besides being a smoker (40 pack years). The ESP block was performed 45 min preoperatively at the level of the T7 transverse process as described above under mild sedation with fentanyl 50 μg IV. She received standard premedication with paracetamol and ibuprofen. Induction was performed with propofol 190 mg and remifentanil 250 μg and maintained with propofol 70 μg/kg/min and remifentanil 0.3 μg/kg/min. Intubation and extubation were uneventful. Intraoperative medication was similar to patient 1. The first NRS in the PACU was 2/10 and subsequent scores were 0–2/10. Morphine 10 mg was administered orally due to earlier standard protocols, although the patient did not have any pain complaints. The patient was discharged to home from the PACU 3 hours and 32 min after arrival.

2.3. Patient 3

A 65-year-old woman (BMI 33.3 kg/m2) also presented for ambulatory laparoscopic cholecystectomy. Her only comorbidities were depression and anxiety, which were well controlled with oral nortriptyline and pregabalin. Premedication with paracetamol and ibuprofen was similar to the other two cases described above. The ESP block was carried out 45 min preoperatively at the level of the T7 transverse process similar to patients 1 and 2. Induction was achieved with propofol 140 mg and remifentanil 250 μg and maintained with propofol 71 μg/kg/min and remifentanil 0.13 μg/kg/min. She also received intraoperative dexamethasone, droperidol, ondansetron, and port site infiltration. Fentanyl 100 μg was administered intraoperatively. After uncomplicated surgery and extubation the patient was transferred to the PACU. In the PACU the patient only complained of minor pain (NRS < 3/10). She received fentanyl 50 μg, and at discharge to home 2 hours and 1 min later her NRS score was 0/10. Data on all three cases are summarized in Table 1.
Table 1

Data from all three patients on opioid consumption, pain scores, and other variables.

Patient 1Patient 2Patient 3
Discomfort with block placement (0–10)104
In-hospital opioids
Intraoperative (during surgery)15 mg15 mg15 mg
 Postoperative (in PACU) 25 mg10 mg15 mg
NRS in PACU (0–10)
 First NRS 223
 Highest NRS 323
PONV in PACUNoNoNo
Time to discharge from PACU2 h 56 min3 h 32 min2 h 1 min
Opioid requirements after discharge
 1st postoperative day 10 mg20 mg20 mg
 2nd postoperative day 0 mg10 mg 0 mg
 In total 1st week 10 mg40 mg20 mg
Mean NRS after discharge (0–10)
 1st postoperative day 434
 2nd postoperative day 322
 7th postoperative day 000
PDNV
 1st postoperative day NoNoNo
 2nd postoperative day NoNoNo
Unscheduled healthcare contactsNoNoNo
(within 1st week after surgery)
Resumption of ADL (days)5710

NRS: numerical rating scale. PACU: postanesthesia care unit. PDNV: postdischarge nausea and vomiting. ADL: activities of daily living.  Oral morphine equivalents. PONV: postoperative nausea and vomiting.

3. Discussion

In developed countries, approximately 15% of asymptomatic adults from the general population have gallstones, and nearly 10% of these individuals develop symptoms or complications requiring treatment within five years [12]. Cholecystectomy is the golden standard in treating symptomatic gallbladder disease, such as acute cholecystitis [12]. In Denmark, about 9000 cholecystectomies are performed annually, and 93% of these are performed as laparoscopic procedures [13]. Currently, about 40% of the laparoscopic cholecystectomies are performed as ambulatory surgery [13], and approximately 15% of the ambulatory patients cannot be discharged on the day of the surgery most often due to pain or postoperative nausea and vomiting (PONV) [12]. Pain can be severe after laparoscopic cholecystectomy [2, 3]. This pain has three components: incisional pain (somatic pain from the trocar site), visceral pain, and shoulder pain (presumably referred visceral pain) [2, 3]. Pain in general is most intense on the day of the surgery (peaking within the first 4–8 hours after surgery) and subsequently diminishes to low levels within 2–4 days [2, 3, 14]. The intensity of visceral pain dominates over incisional pain (especially periumbilical), which dominates over shoulder pain [2]. Three possible mechanisms for visceral pain have been proposed: (1) irritative effect on the diaphragmatic peritoneum of the insufflated CO2 gas because of conversion to carbonic acid, (2) diaphragmatic muscle fiber stretching with tearing of muscular blood vessels and traction on nerve fibers, and (3) retained residual pockets of gas in the abdominal cavity [2, 3, 15]. About 30–50% of patients suffer from shoulder pain during the first postoperative day, most often on the right side [15]. It is usually of short duration and low intensity [2, 15]. The mechanism of shoulder pain is multifactorial and poorly understood, but it is thought to be subdiaphragmatic irritation transmitted via the phrenic nerve causing referred pain in the C4 dermatome [2, 15]. For comparison, regarding how the normal patient without a block does at our institution, we have carried out a survey from the first 50 laparoscopic cholecystectomies at our department in 2016 (yet unpublished data) with multimodal analgesia (paracetamol, ibuprofen, dexamethasone, port site infiltration, and opioids as rescue medication). Immediately after awakening, about half of patients (56%) had minor pain (NRS 0–3) and about half of patients (44%) had moderate to severe pain (NRS 4–10). About one-fourth of the patients (24%) just had minor pain (NRS 0–3) during the entire PACU stay, whereas about three-fourths of the patients (76%) at some point had moderate to severe pain (NRS 4–10). Interestingly, only half of the patients who initially just had minor pain (NRS 0–3) continued having minor pain, whereas the other half of the patients with initial minor pain experienced stronger pain later during the PACU stay. Another point of interest is that 1 out of 7 patients (14%) at some point in the PACU had excruciating pain (NRS 8–10), which corresponds to earlier reported numbers [16]. The patients received on average 47 mg morphine (oral equivalents) intraoperatively (standard deviation 14.8) and 45 mg postoperatively (SD 31.8) during the PACU stay. Prevalence of PONV in the PACU was 40%, requiring additional pharmacological treatment besides the administered standard triple prophylaxis. The average discharge time was 3.5 hours (SD 1.4), and 20% were admitted overnight most often due to pain. The clinical course of patients discharged after ambulatory laparoscopic cholecystectomy (without block) in our department has been previously described [14]. Median pain intensity was NRS 7 on the day of surgery and NRS 6, 5, 4, 1 on the 1st, 2nd, 3rd, 7th postoperative day, respectively [14]. After discharge 27.9% of the patients had unscheduled pain-related contacts with healthcare services, most often in the 1st postoperative week [14]. Opioid requirements at home after ambulatory laparoscopic cholecystectomy are variable [17]. According to Hill et al. about 35% of discharged patients did not take opioids, about 25% took 1–10 pills of oxycodone 5 mg (equivalent to 7.5 mg oral morphine), about 25% took 11–15 pills, and about 15% took more than 15 pills [17]. PONV has previously been described to exist in about 10% of patients after laparoscopic cholecystectomy with multimodal anesthesia [2, 16]. Pain is strongly associated with PONV [16]. Pain may directly worsen PONV, and PONV in itself may aggravate the pain [16]. The concept of “fast-track surgery” or Enhanced Recovery after Surgery (ERAS) programs applied on laparoscopic cholecystectomy requires multimodal analgesia including paracetamol, NSAIDs and dexamethasone in addition to opioids as rescue medication [1–3, 18]. Port site local infiltration has been shown to provide some pain relief, as opposed to intraperitoneal local anesthetic [3, 19]. Low pressure pneumoperitoneum (<10 mmHg) has been shown to decrease pain scores and analgesic consumption as opposed to standard pressure (12–16 mmHg) [3, 15, 20]. Active gas aspiration and pulmonary recruitment maneuvers after the completion of the surgical procedure empty the abdominal cavity from residual CO2 gas and reduce postoperative overall pain [15, 21]. This is especially true for shoulder pain and possibly also for (upper) abdominal pain [21]. Classical lateral Transversus Abdominis Plane (TAP) blocks have shown marginal benefit in reducing opioid consumption and pain scores in the first 6–8 hours similar to that of local port site infiltration [19, 22]. TAP blocks only provide somatic analgesia [19]. Since its first description in 2016 numerous case reports about the ESP block have been described for thoracic and abdominal procedures including thoracic neuropathic pain [4, 6], ventral hernia repair [7], bariatric surgery [8], thoracotomy with lobectomy [5], rib tumor surgery [23], and major lower abdominal surgery [9]. Unlike earlier beliefs, the fascial planes in the paravertebral region may not be bound true compartments [24]. Local anesthetic seems to spread along the dorsal rami of the thoracic spinal nerves, which run through the costotransverse foramina of Cruveilhier. Ligaments like the superior costotransverse ligament seem to have fenestrations [24], and these porous anatomical structures can be speculated to allow anterior spread of the local anesthetic. The needle tip positioning for the ESP block is technically simple, safe, and away from the paravertebral space and the pleura. The ESP block injectate reaches the dorsal and ventral rami of the thoracic spinal nerves as well as the sympathetic gray communicating rami [4, 7, 23]. The ESP block generates extensive blockade of the posterior, lateral, and anterior thoracic and abdominal wall and thus alleviates incisional pain. In addition, the ESP blocks visceral autonomic pain [6, 8]. There are several unanswered questions to address. Firstly, the ESP block has so far only been described in case reports, and the promising results must be validated in future randomized clinical trials. Secondly, the optimal time for block placement should be considered. In general, this is the best achieved preoperatively in the awake patient. About three-fourths of the patients experience moderate to severe pain some time during the postoperative period. A minority of the patients experience excruciating pain. Thirdly, optimal volume and concentration of local anesthetic are unknown. Previous authors have mainly used ropivacaine 0.5% 20 mL providing analgesia for about 20 hours reducing opioid consumption to about one-third [7]. A similar reduction from the expected opioid usage was seen in our three cases (see Table 1). The opioid sparing potential may be especially advantageous in the ambulatory setting, where pain and/or PONV may delay or even prevent same-day discharge. Fourthly, additives like glucocorticosteroids (off-label use) can be considered [7], which presumably would extend block duration beyond 24 hours.

4. Conclusion

The three reported cases illustrate the efficacy of the ESP block for somatic and visceral pain relief after upper abdominal laparoscopic cholecystectomy. The results must be validated in future randomized controlled trials.
  23 in total

Review 1.  Pulmonary recruitment maneuver to reduce pain after laparoscopy: a meta-analysis of randomized controlled trials.

Authors:  Vasilios Pergialiotis; Dimitrios-Efthymios G Vlachos; Konstantinos Kontzoglou; Despina Perrea; Georgios D Vlachos
Journal:  Surg Endosc       Date:  2014-11-01       Impact factor: 4.584

2.  Enhanced Recovery After Surgery (ERAS): good for now, but what about the future?

Authors:  Henrik Kehlet
Journal:  Can J Anaesth       Date:  2014-11-13       Impact factor: 5.063

3.  Erector spinae plane block for postoperative analgesia in pediatric oncological thoracic surgery.

Authors:  Felipe Muñoz; Javier Cubillos; Antonio J Bonilla; Ki Jinn Chin
Journal:  Can J Anaesth       Date:  2017-04-26       Impact factor: 5.063

Review 4.  Essentials of Our Current Understanding: Abdominal Wall Blocks.

Authors:  Ki Jinn Chin; John G McDonnell; Brendan Carvalho; Aidan Sharkey; Amit Pawa; Jeffrey Gadsden
Journal:  Reg Anesth Pain Med       Date:  2017 Mar/Apr       Impact factor: 6.288

5.  The analgesic efficacy of pre-operative bilateral erector spinae plane (ESP) blocks in patients having ventral hernia repair.

Authors:  K J Chin; S Adhikary; N Sarwani; M Forero
Journal:  Anaesthesia       Date:  2017-02-11       Impact factor: 6.955

6.  Does paravertebral block require access to the paravertebral space?

Authors:  I Costache; J Sinclair; F A Farrash; T B Nguyen; C J L McCartney; C J Ramnanan; S L Goodwin
Journal:  Anaesthesia       Date:  2016-07       Impact factor: 6.955

7.  The Analgesic Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block in Adult Patients: A Meta-Analysis.

Authors:  Moira Baeriswyl; Kyle R Kirkham; Christian Kern; Eric Albrecht
Journal:  Anesth Analg       Date:  2015-12       Impact factor: 5.108

Review 8.  Pain and convalescence after laparoscopic cholecystectomy.

Authors:  T Bisgaard; H Kehlet; J Rosenberg
Journal:  Eur J Surg       Date:  2001-02

Review 9.  Anaesthetic regimens for day-procedure laparoscopic cholecystectomy.

Authors:  Jessica Vaughan; Myura Nagendran; Jacqueline Cooper; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2014-01-24

Review 10.  Surgical techniques to minimize shoulder pain after laparoscopic cholecystectomy. A systematic review.

Authors:  Anders Meller Donatsky; Flemming Bjerrum; Ismail Gögenur
Journal:  Surg Endosc       Date:  2013-01-24       Impact factor: 4.584

View more
  11 in total

Review 1.  Ambulatory Pain Management in the Pediatric Patient Population.

Authors:  Jodi-Ann Oliver; Lori-Ann Oliver; Nitish Aggarwal; Khushboo Baldev; Melanie Wood; Lovemore Makusha; Nalini Vadivelu; Lance Lichtor
Journal:  Curr Pain Headache Rep       Date:  2022-02-07

2.  Erector spinae plane block reduces pain after laparoscopic cholecystectomy.

Authors:  Vladimir Vrsajkov; Nataša Ilić; Arsen Uvelin; Radomir Ilić; Mirka Lukić-Šarkanović; Aleksandra Plećaš-Đurić
Journal:  Anaesthesist       Date:  2021-10-18       Impact factor: 1.041

3.  Erector spinae plane block and transversus abdominis plane block for postoperative analgesia in cesarean section: A prospective randomized comparative study.

Authors:  Aman Malawat; Kalpana Verma; Durga Jethava; Dharam Das Jethava
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2020-06-15

4.  Erector Spinae Plane Block in Laparoscopic Cholecystectomy, Is There a Difference? A Randomized Controlled Trial.

Authors:  Mohamed Ibrahim
Journal:  Anesth Essays Res       Date:  2020-02-03

5.  Erector spinae block for postoperative analgesia following axillary hidradenitis suppurativa resection: a case report.

Authors:  Johanna Blair de Haan; Nadia Hernandez; Sudipta Sen
Journal:  Local Reg Anesth       Date:  2018-11-15

6.  Efficacy of bilateral erector spinae plane block in the management of pain: current insights.

Authors:  Serkan Tulgar; Ali Ahiskalioglu; Alessandro De Cassai; Yavuz Gurkan
Journal:  J Pain Res       Date:  2019-08-27       Impact factor: 3.133

7.  Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial.

Authors:  Başak Altıparmak; Melike Korkmaz Toker; Ali İhsan Uysal; Semra Gümüş Demirbilek
Journal:  BMC Anesthesiol       Date:  2019-03-04       Impact factor: 2.217

8.  The erector spinae plane block: a narrative review.

Authors:  Pablo Kot; Pablo Rodriguez; Manuel Granell; Beatriz Cano; Lucas Rovira; Javier Morales; Ana Broseta; Jose De Andrés
Journal:  Korean J Anesthesiol       Date:  2019-03-19

9.  Erector spinae plane block for complete surgical anaesthesia and postoperative analgesia for breast surgeries: A prospective feasibility study of 30 cases.

Authors:  Aman Malawat; Kalpana Verma; Durga Jethava; Dharam D Jethava
Journal:  Indian J Anaesth       Date:  2020-02-04

10.  Erector spinae plane block for breast oncological procedure as a surrogate to general anaesthesia: A retrospective study.

Authors:  Aman Malawat; Durga Jethava; Sudhir Sachdev; Dharam Das Jethava
Journal:  Indian J Anaesth       Date:  2020-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.